1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Chugai Secures Japanese Rights for CT-388, a Next-Gen Obesity & Diabetes Therapy

11 Oct 2025
Admin
News Article

Chugai Secures Japanese Rights for CT-388, a Next-Gen Obesity & Diabetes Therapy

Chugai Pharmaceutical Co., Ltd. has inked a license agreement with Roche for CT-388, a long-acting GLP-1/GIP receptor agonist in development for obesity and type 2 diabetes. Under the deal, Chugai gets exclusive development and marketing rights in Japan, while Roche will receive an upfront fee plus milestone payments.

CT-388: Dual Action for Weight & Glucose Control

CT-388 is designed to:

Target both GLP-1 and GIP receptors, promoting sustained weight loss and better glycaemic control.
Minimize receptor desensitization via biased signalling, which may help maintain long-term effectiveness.

“CT-388 offers a potential new treatment for patients with obesity or type 2 diabetes. We aim to deliver it to Japanese patients as soon as possible.”

Dr. Osamu Okuda, CEO of Chugai.

Promising Clinical Results

In an overseas Phase I trial (CT-388-101):

Participants received weekly subcutaneous injections for 24 weeks.
Placebo-adjusted weight reduction: -18.8% at week 24 (p<0.001).
Weight reduction milestones: 100% >5%, 85% >10%, 70% >15%, 45% >20%.
Side effects were mainly mild to moderate gastrointestinal symptoms, typical of incretin-based therapies.

The trial enrolled 129 adults with overweight or obesity, including those with type 2 diabetes. Primary endpoints assessed safety and tolerability, while secondary endpoints included weight loss and glucose homeostasis.

Next Steps

CT-388 is currently in Phase II trials overseas for obesity in patients with type 2 diabetes. Chugai plans to leverage Roche’s R&D resources to advance the drug in Japan and address unmet medical needs in obesity and metabolic disease.

About CT-388

Mechanism: Weekly subcutaneous GLP-1/GIP dual agonist with biased signalling.
Goal: Deliver long-lasting efficacy with minimal receptor desensitization.
Potential Impact: Clinically meaningful weight reduction and improved glycaemic control for patients struggling with obesity or type 2 diabetes.